Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
BRCA1 mutant ovarian cancer
PLA2G7)
Wnt signaling
pGSK3β
platelet-activating factor acetylhydrolase (PAF-AH
prognosis
β-catenin
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
08
05
2021
revised:
12
06
2021
accepted:
17
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Aberrantly activated Wnt/β-catenin signaling pathway, as well as platelet-activating factor (PAF), contribute to cancer progression and metastasis of many cancer entities. Nonetheless, the role of the degradation enzyme named platelet-activating factor acetylhydrolase (PLA2G7/PAF-AH) in ovarian cancer etiology is still unclear. This study investigated the functional impact of platelet-activating factor acetylhydrolase on BRCA1 mutant ovarian cancer biology and its crosstalk with the Wnt signaling pathway. PAF-AH, pGSK3β, and β-catenin expressions were analyzed in 156 ovarian cancer specimens by immunohistochemistry. PAF-AH expression was investigated in ovarian cancer tissue, serum of BRCA1-mutated patients, and in vitro in four ovarian cancer cell lines. Functional assays were performed after PLA2G7 silencing. The association of PAF-AH and β-catenin was examined by immunocytochemistry. In an established ovarian carcinoma collective, we identified PAF-AH as an independent positive prognostic factor for overall survival (median 59.9 vs. 27.4 months;
Identifiants
pubmed: 34206491
pii: biomedicines9070706
doi: 10.3390/biomedicines9070706
pmc: PMC8301368
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : "Brigitte & Dr. Konstanze Wegener" foundation
ID : none
Références
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:83-94
pubmed: 12432911
BMC Cancer. 2018 Oct 19;18(1):999
pubmed: 30340558
J Ovarian Res. 2014 Apr 11;7:39
pubmed: 24721622
J Pathol Clin Res. 2017 Apr 04;3(2):123-138
pubmed: 28451461
J Clin Med. 2019 Oct 11;8(10):
pubmed: 31614568
Front Cell Neurosci. 2010 May 28;4:
pubmed: 20725507
Int J Mol Med. 2002 Apr;9(4):353-8
pubmed: 11891526
Mol Cancer Res. 2010 Mar;8(3):407-20
pubmed: 20215423
Genome Biol. 2016 May 23;17(1):108
pubmed: 27215396
Nature. 1995 Apr 6;374(6522):549-53
pubmed: 7700381
Cancer Metastasis Rev. 2007 Dec;26(3-4):359-71
pubmed: 17721743
Cell. 2006 Nov 3;127(3):469-80
pubmed: 17081971
Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16
pubmed: 23933223
Acta Oncol. 2012 Apr;51(4):441-53
pubmed: 22313338
Nat Rev Genet. 2004 Sep;5(9):691-701
pubmed: 15372092
Cancer Res. 2008 Jul 15;68(14):5839-48
pubmed: 18632638
J Wound Ostomy Continence Nurs. 1997 Jan;24(1):12
pubmed: 9213501
Infect Disord Drug Targets. 2009 Aug;9(4):390-9
pubmed: 19689381
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Hematol Oncol. 2014 May 06;7:39
pubmed: 24886678
Gynecol Oncol. 2006 Jan;100(1):33-7
pubmed: 16153692
Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24
pubmed: 12781368
Am J Epidemiol. 2006 Apr 1;163(7):670-5
pubmed: 16410346
J Cell Physiol. 2000 May;183(2):254-64
pubmed: 10737901
Oncotarget. 2011 Dec;2(12):1176-90
pubmed: 22202492
Breast Cancer (Dove Med Press). 2019 Feb 19;11:87-97
pubmed: 30858725
J Cell Mol Med. 2010 Jun;14(6B):1396-407
pubmed: 19754670
Clin Cancer Res. 2003 Sep 15;9(11):4214-20
pubmed: 14519648
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Oncotarget. 2015 Sep 15;6(27):23720-34
pubmed: 26125441
Onco Targets Ther. 2019 Apr 11;12:2799-2808
pubmed: 31043794
Nat Struct Mol Biol. 2005 Apr;12(4):364-71
pubmed: 15768032
J Biol Chem. 2004 Dec 10;279(50):52425-36
pubmed: 15456758
Am J Psychol. 1987 Fall-Winter;100(3-4):441-71
pubmed: 3322052
J Cell Physiol. 2007 Dec;213(3):589-602
pubmed: 17786953
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16654-9
pubmed: 23011797
Br J Cancer. 2014 Jul 29;111(3):515-24
pubmed: 24921917
Breast Cancer Res. 2000;2(2):82-5
pubmed: 11250695
Reprod Biol Endocrinol. 2010 Jun 24;8:74
pubmed: 20576130
FASEB J. 2004 Mar;18(3):568-70
pubmed: 14715700
Cancer Res. 2015 Oct 1;75(19):4198-210
pubmed: 26359459
Biochem Biophys Res Commun. 2018 Jun 27;501(3):654-660
pubmed: 29758199
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
Am J Pathol. 2005 May;166(5):1515-22
pubmed: 15855650
Cancer Res. 2013 May 1;73(9):2806-16
pubmed: 23361301
Chem Biol. 2014 Jul 17;21(7):831-40
pubmed: 24954006
Cancers (Basel). 2019 Mar 23;11(3):
pubmed: 30909618
Obstet Gynecol. 1990 Feb;75(2):263-73
pubmed: 2300355
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Carcinog. 2019 Oct;58(10):1770-1782
pubmed: 31219654
Lancet. 2001 Jan 20;357(9251):176-82
pubmed: 11213094
Cancer Sci. 2016 Oct;107(10):1363-1372
pubmed: 27486911
Acta Physiol (Oxf). 2009 Nov;197(3):175-85
pubmed: 19432589
Cardiovasc Drugs Ther. 2009 Feb;23(1):73-83
pubmed: 18949548
Clin Exp Metastasis. 2009;26(7):653-61
pubmed: 19444623
BMC Res Notes. 2012 Oct 05;5:551
pubmed: 23036050
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Nat Genet. 2004 Apr;36(4):320-2
pubmed: 15054482
JAMA. 2019 Aug 20;322(7):666-685
pubmed: 31429902